After promising efficacy data from the TROPIC trial (NCT00417079), cabazitaxel was approved for use in metastatic castration-resistant prostate cancer (mCRPC) post-docitaxel therapy. Until now, however, safety data for this drug have been lacking, as Stephane Oudard, MD, PhD, of Georges Pompidou Hospital, Paris, France, explained at the American Society of Oncology (ASCO) 2018 Annual Meeting, held in Chicago, IL. In this interview, he discusses the retrospective FUJI study, which used real world data to show that cabazitaxel is not only effective, but also safe, in this setting. Prof. Oudard emphasizes the relevance of these results to daily clinical practice.
